Chd5 Requires PHD-Mediated Histone 3 Binding for Tumor Suppression

Cell Reports

Volumn 3, Issue 1, 2013, Pages 92-102

  Paul, Shilpi ^a   Kuo, Alex ^c   Schalch, Thomas ^a,b,c,e   Vogel, Hannes ^d   Joshua Tor, Leemor ^a,b,c   McCombie, W Richard ^a   Gozani, Or ^c   Hammell, Molly ^a   Mills, Alea A ^a  

^a Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

^b W M Keck Structural Biology Laboratory   (United States)

^c STANFORD UNIVERSITY   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMODOMAIN HELICASE DNA BINDING PROTEIN 5; DNA BINDING PROTEIN; HISTONE H3; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; GENE LOCUS; GENE MAPPING; GENE MUTATION; HUMAN; MALIGNANT TRANSFORMATION; NEUROBLASTOMA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; SEQUENCE ANALYSIS; TRANSCRIPTION INITIATION SITE;

AMINO ACID SEQUENCE; ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DNA HELICASES; GENETIC LOCI; GENOME; HISTONES; HOMEODOMAIN PROTEINS; HUMANS; LYSINE; METHYLATION; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASMS; NEUROBLASTOMA; PEPTIDES; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84873205781     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2012.12.009     Document Type: Article

References (64)

1. Agrawal N., Frederick M.J., Pickering C.R., Bettegowda C., Chang K., Li R.J., Fakhry C., Xie T.X., Zhang J., Wang J., et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011, 333:1154-1157.
2. Bagchi A., Mills A.A. The quest for the 1p36 tumor suppressor. Cancer Res. 2008, 68:2551-2556.
3. Bagchi A., Papazoglu C., Wu Y., Capurso D., Brodt M., Francis D., Bredel M., Vogel H., Mills A.A. CHD5 is a tumor suppressor at human 1p36. Cell 2007, 128:459-475.
4. Baker L.A., Allis C.D., Wang G.G. PHD fingers in human diseases: disorders arising from misinterpreting epigenetic marks. Mutat. Res. 2008, 647:3-12.
5. Barski A., Cuddapah S., Cui K., Roh T.Y., Schones D.E., Wang Z., Wei G., Chepelev I., Zhao K. High-resolution profiling of histone methylations in the human genome. Cell 2007, 129:823-837.
6. Berger M.F., Lawrence M.S., Demichelis F., Drier Y., Cibulskis K., Sivachenko A.Y., Sboner A., Esgueva R., Pflueger D., Sougnez C., et al. The genomic complexity of primary human prostate cancer. Nature 2011, 470:214-220.
7. Bouazoune K., Mitterweger A., Längst G., Imhof A., Akhtar A., Becker P.B., Brehm A. The dMi-2 chromodomains are DNA binding modules important for ATP-dependent nucleosome mobilization. EMBO J. 2002, 21:2430-2440.
8. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068. Cancer Genome Atlas Research Network.
9. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615. Cancer Genome Atlas Research Network.
10. Dignam J.D., Lebovitz R.M., Roeder R.G. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 1983, 11:1475-1489.
11. Du X., Wu T., Lu J., Zang L., Song N., Yang T., Zhao H., Wang S. Decreased expression of chromodomain helicase DNA-binding protein 5 is an unfavorable prognostic marker in patients with primary gallbladder carcinoma. Clin. Transl. Oncol. 2012, Jul 24 [Epub ahead of print].
12. Flanagan J.F., Mi L.Z., Chruszcz M., Cymborowski M., Clines K.L., Kim Y., Minor W., Rastinejad F., Khorasanizadeh S. Double chromodomains cooperate to recognize the methylated histone H3 tail. Nature 2005, 438:1181-1185.
13. Fujita T., Igarashi J., Okawa E.R., Gotoh T., Manne J., Kolla V., Kim J., Zhao H., Pawel B.R., London W.B., et al. CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J. Natl. Cancer Inst. 2008, 100:940-949.
14. Garcia I., Mayol G., Rodríguez E., Suñol M., Gershon T.R., Ríos J., Cheung N.K., Kieran M.W., George R.E., Perez-Atayde A.R., et al. Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma. Mol. Cancer 2010, 9:277.
15. Garcia I., Mayol G., Ríos J., Domenech G., Cheung N.K., Oberthuer A., Fischer M., Maris J.M., Brodeur G.M., Hero B., et al. A three-gene expression signature model for risk stratification of patients with neuroblastoma. Clin. Cancer Res. 2012, 18:2012-2023.
16. Godfried M.B., Veenstra M., Valent A., Sluis Pv., Voûte P.A., Versteeg R., Caron H.N. Lack of interstitial chromosome 1p deletions in clinically-detected neuroblastoma. Eur. J. Cancer 2002, 38:1513-1519.
17. Goldschneider D., Horvilleur E., Plassa L.F., Guillaud-Bataille M., Million K., Wittmer-Dupret E., Danglot G., de Thé H., Bénard J., May E., Douc-Rasy S. Expression of C-terminal deleted p53 isoforms in neuroblastoma. Nucleic Acids Res. 2006, 34:5603-5612.
18. Gorringe K.L., Choong D.Y., Williams L.H., Ramakrishna M., Sridhar A., Qiu W., Bearfoot J.L., Campbell I.G. Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer. Neoplasia 2008, 10:1253-1258.
19. Hemann M.T., Zilfou J.T., Zhao Z., Burgess D.J., Hannon G.J., Lowe S.W. Suppression of tumorigenesis by the p53 target PUMA. Proc. Natl. Acad. Sci. USA 2004, 101:9333-9338.
20. Hers I., Vincent E.E., Tavaré J.M. Akt signalling in health and disease. Cell. Signal. 2011, 23:1515-1527.
21. Jacobs S.A., Khorasanizadeh S. Structure of HP1 chromodomain bound to a lysine 9-methylated histone H3 tail. Science 2002, 295:2080-2083.
22. Jacobs S.A., Fischle W., Khorasanizadeh S. Assays for the determination of structure and dynamics of the interaction of the chromodomain with histone peptides. Methods Enzymol. 2004, 376:131-148.
23. Jones S., Wang T.L., Shih IeM., Mao T.L., Nakayama K., Roden R., Glas R., Slamon D., Diaz L.A., Vogelstein B., et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010, 330:228-231.
24. Kaghad M., Bonnet H., Yang A., Creancier L., Biscan J.C., Valent A., Minty A., Chalon P., Lelias J.M., Dumont X., et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997, 90:809-819.
25. Koh A.S., Kuo A.J., Park S.Y., Cheung P., Abramson J., Bua D., Carney D., Shoelson S.E., Gozani O., Kingston R.E., et al. Aire employs a histone-binding module to mediate immunological tolerance, linking chromatin regulation with organ-specific autoimmunity. Proc. Natl. Acad. Sci. USA 2008, 105:15878-15883.
26. Koyama H., Zhuang T., Light J.E., Kolla V., Higashi M., McGrady P.W., London W.B., Brodeur G.M. Mechanisms of CHD5 Inactivation in neuroblastomas. Clin. Cancer Res. 2012, 18:1588-1597.
27. Lan F., Collins R.E., De Cegli R., Alpatov R., Horton J.R., Shi X., Gozani O., Cheng X., Shi Y. Recognition of unmethylated histone H3 lysine 4 links BHC80 to LSD1-mediated gene repression. Nature 2007, 448:718-722.
28. Lang J., Tobias E.S., Mackie R. Preliminary evidence for involvement of the tumour suppressor gene CHD5 in a family with cutaneous melanoma. Br. J. Dermatol. 2011, 164:1010-1016.
29. Li M., Zhao H., Zhang X., Wood L.D., Anders R.A., Choti M.A., Pawlik T.M., Daniel H.D., Kannangai R., Offerhaus G.J., et al. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat. Genet. 2011, 43:828-829.
30. Lusser A., Urwin D.L., Kadonaga J.T. Distinct activities of CHD1 and ACF in ATP-dependent chromatin assembly. Nat. Struct. Mol. Biol. 2005, 12:160-166.
31. Mansfield R.E., Musselman C.A., Kwan A.H., Oliver S.S., Garske A.L., Davrazou F., Denu J.M., Kutateladze T.G., Mackay J.P. Plant homeodomain (PHD) fingers of CHD4 are histone H3-binding modules with preference for unmodified H3K4 and methylated H3K9. J. Biol. Chem. 2011, 286:11779-11791.
32. Marfella C.G., Imbalzano A.N. The Chd family of chromatin remodelers. Mutat. Res. 2007, 618:30-40.
33. Matthews A.G., Kuo A.J., Ramón-Maiques S., Han S., Champagne K.S., Ivanov D., Gallardo M., Carney D., Cheung P., Ciccone D.N., et al. RAG2 PHD finger couples histone H3 lysine 4 trimethylation with V(D)J recombination. Nature 2007, 450:1106-1110.
34. Mills A.A. Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins. Nat. Rev. Cancer 2010, 10:669-682.
35. Mokarram P., Kumar K., Brim H., Naghibalhossaini F., Saberi-firoozi M., Nouraie M., Green R., Lee E., Smoot D.T., Ashktorab H. Distinct high-profile methylated genes in colorectal cancer. PLoS ONE 2009, 4:e7012.
36. Mulero-Navarro S., Esteller M. Chromatin remodeling factor CHD5 is silenced by promoter CpG island hypermethylation in human cancer. Epigenetics 2008, 3:210-215.
37. Murawska M., Brehm A. CHD chromatin remodelers and the transcription cycle. Transcription 2011, 2:244-253.
38. Musgrove E.A., Caldon C.E., Barraclough J., Stone A., Sutherland R.L. Cyclin D as a therapeutic target in cancer. Nat. Rev. Cancer 2011, 11:558-572.
39. Musselman C.A., Mansfield R.E., Garske A.L., Davrazou F., Kwan A.H., Oliver S.S., O'Leary H., Denu J.M., Mackay J.P., Kutateladze T.G. Binding of the CHD4 PHD2 finger to histone H3 is modulated by covalent modifications. Biochem. J. 2009, 423:179-187.
40. Musselman C.A., Ramírez J., Sims J.K., Mansfield R.E., Oliver S.S., Denu J.M., Mackay J.P., Wade P.A., Hagman J., Kutateladze T.G. Bivalent recognition of nucleosomes by the tandem PHD fingers of the CHD4 ATPase is required for CHD4-mediated repression. Proc. Natl. Acad. Sci. USA 2012, 109:787-792.
41. Nielsen P.R., Nietlispach D., Mott H.R., Callaghan J., Bannister A., Kouzarides T., Murzin A.G., Murzina N.V., Laue E.D. Structure of the HP1 chromodomain bound to histone H3 methylated at lysine 9. Nature 2002, 416:103-107.
42. Okawa E.R., Gotoh T., Manne J., Igarashi J., Fujita T., Silverman K.A., Xhao H., Mosse Y.P., White P.S., Brodeur G.M. Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas. Oncogene 2008, 27:803-810.
43. Oliver S.S., Musselman C.A., Srinivasan R., Svaren J.P., Kutateladze T.G., Denu J.M. Multivalent recognition of histone tails by the PHD fingers of CHD5. Biochemistry 2012, 51:6534-6544.
44. Ooi S.K., Qiu C., Bernstein E., Li K., Jia D., Yang Z., Erdjument-Bromage H., Tempst P., Lin S.P., Allis C.D., et al. DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature 2007, 448:714-717.
45. Org T., Chignola F., Hetényi C., Gaetani M., Rebane A., Liiv I., Maran U., Mollica L., Bottomley M.J., Musco G., Peterson P. The autoimmune regulator PHD finger binds to non-methylated histone H3K4 to activate gene expression. EMBO Rep. 2008, 9:370-376.
46. Rajakumara E., Wang Z., Ma H., Hu L., Chen H., Lin Y., Guo R., Wu F., Li H., Lan F., et al. PHD finger recognition of unmodified histone H3R2 links UHRF1 to regulation of euchromatic gene expression. Mol. Cell 2011, 43:275-284.
47. Robbins C.M., Tembe W.A., Baker A., Sinari S., Moses T.Y., Beckstrom-Sternberg S., Beckstrom-Sternberg J., Barrett M., Long J., Chinnaiyan A., et al. Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res. 2011, 21:47-55.
48. Saksouk N., Avvakumov N., Champagne K.S., Hung T., Doyon Y., Cayrou C., Paquet E., Ullah M., Landry A.J., Côté V., et al. HBO1 HAT complexes target chromatin throughout gene coding regions via multiple PHD finger interactions with histone H3 tail. Mol. Cell 2009, 33:257-265.
49. Sanchez R., Zhou M.M. The PHD finger: a versatile epigenome reader. Trends Biochem. Sci. 2011, 36:364-372.
50. Shi X., Hong T., Walter K.L., Ewalt M., Michishita E., Hung T., Carney D., Peña P., Lan F., Kaadige M.R., et al. ING2 PHD domain links histone H3 lysine 4 methylation to active gene repression. Nature 2006, 442:96-99.
51. Shi X., Kachirskaia I., Walter K.L., Kuo J.H., Lake A., Davrazou F., Chan S.M., Martin D.G., Fingerman I.M., Briggs S.D., et al. Proteome-wide analysis in Saccharomyces cerevisiae identifies several PHD fingers as novel direct and selective binding modules of histone H3 methylated at either lysine 4 or lysine 36. J. Biol. Chem. 2007, 282:2450-2455.
52. Sims J.K., Wade P.A. SnapShot: chromatin remodeling: CHD. Cell 2011, 144. 626-626.
53. Sjöblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., Mandelker D., Leary R.J., Ptak J., Silliman N., et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314:268-274.
54. Tsai W.W., Wang Z., Yiu T.T., Akdemir K.C., Xia W., Winter S., Tsai C.Y., Shi X., Schwarzer D., Plunkett W., et al. TRIM24 links a non-canonical histone signature to breast cancer. Nature 2010, 468:927-932.
55. Wang G.G., Song J., Wang Z., Dormann H.L., Casadio F., Li H., Luo J.L., Patel D.J., Allis C.D. Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger. Nature 2009, 459:847-851.
56. Wang X., Lau K.K., So L.K., Lam Y.W. CHD5 is down-regulated through promoter hypermethylation in gastric cancer. J. Biomed. Sci. 2009, 16:95.
57. Wong R.R., Chan L.K., Tsang T.P., Lee C.W., Cheung T.H., Yim S.F., Siu N.S., Lee S.N., Yu M.Y., Chim S.S., et al. CHD5 Downregulation Associated with Poor Prognosis in Epithelial Ovarian Cancer. Gynecol. Obstet. Invest. 2011, 72:203-207.
58. Wysocka J., Swigut T., Xiao H., Milne T.A., Kwon S.Y., Landry J., Kauer M., Tackett A.J., Chait B.T., Badenhorst P., et al. A PHD finger of NURF couples histone H3 lysine 4 trimethylation with chromatin remodelling. Nature 2006, 442:86-90.
59. Yadav S., Singhal J., Singhal S.S., Awasthi S. hSET1: a novel approach for colon cancer therapy. Biochem. Pharmacol. 2009, 77:1635-1641.
60. Yao H., Ashihara E., Maekawa T. Targeting the Wnt/β-catenin signaling pathway in human cancers. Expert Opin. Ther. Targets 2011, 15:873-887.
61. Zeng P.Y., Vakoc C.R., Chen Z.C., Blobel G.A., Berger S.L. In vivo dual cross-linking for identification of indirect DNA-associated proteins by chromatin immunoprecipitation. Biotechniques 2006, 41. 694, 696, 698.
62. Zhao R., Yan Q., Lv J., Huang H., Zheng W., Zhang B., Ma W. CHD5, a tumor suppressor that is epigenetically silenced in lung cancer. Lung Cancer 2011, 76:324-331.
63. Zuber J., Radtke I., Pardee T.S., Zhao Z., Rappaport A.R., Luo W., McCurrach M.E., Yang M.M., Dolan M.E., Kogan S.C., et al. Mouse models of human AML accurately predict chemotherapy response. Genes Dev. 2009, 23:877-889.
64. Zuber J., McJunkin K., Fellmann C., Dow L.E., Taylor M.J., Hannon G.J., Lowe S.W. Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi. Nat. Biotechnol. 2011, 29:79-83.